Oncology specialists Oncurious and BioInvent (STO: BINV) have teamed up with a US research consortium to accelerate Phase I/IIa clinical development of pediatric cancer drug TB-403.
The companies have announced a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), a collaboration of 25 US academic medical centers, teaching hospitals and other entities.
NMTRC facilitates and conducts collaborative research activities and investigations of new treatments for neuroblastoma, medulloblastoma and other pediatric cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze